Cytori Therapeutics (CYTX) Short Interest Ratio & Short Volume

Short interest is the volume of Cytori Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 15th, investors have sold 226,800 shares of CYTX short. 1.79% of Cytori Therapeutics' shares are currently sold short. Learn More on Cytori Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.79% of Cytori Therapeutics' floating shares are currently sold short.

Cytori Therapeutics saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 226,800 shares, an increase of 49.0% from the previous total of 152,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Cytori Therapeutics currently has issued a total of 22,160,000 shares. Some of Cytori Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cytori Therapeutics currently has a public float of 12,660,000 shares.

1.79% of Cytori Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Cytori Therapeutics: Dominari Holdings Inc. (7.57%), Fortress Biotech, Inc. (17.18%), Bolt Biotherapeutics, Inc. (1.24%), SAB Biotherapeutics, Inc. (0.95%), Curis, Inc. (2.31%), Molecular Templates, Inc. (5.48%), Amgen Inc. (2.71%), Gilead Sciences, Inc. (1.62%), Vertex Pharmaceuticals Incorporated (1.70%), Regeneron Pharmaceuticals, Inc. (2.57%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Tableau Software Inc ($1.15 billion), Chemical Financial Co. ($274.44 million), Andeavor Logistics LP ($181.50 million), Bloom Energy Co. ($143.69 million), Barnes & Noble, Inc. ($32.60 million), and American Electric Technologies, Inc. ($394,060.00). View all of the most shorted stocks.

Short selling CYTX is an investing strategy that aims to generate trading profit from Cytori Therapeutics as its price is falling. CYTX shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Cytori Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CYTX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CYTX, twice per month. The most recent reporting period available is July, 15 2019.